Skip to main content

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

Clinical Trial Grant
Duke Scholars

Administered By

Ophthalmology, Vitreoretinal Diseases & Surgery

Awarded By

Regenxbio, Inc.

Start Date

August 2, 2024

End Date

July 14, 2029
 

Administered By

Ophthalmology, Vitreoretinal Diseases & Surgery

Awarded By

Regenxbio, Inc.

Start Date

August 2, 2024

End Date

July 14, 2029